153707-56-3Relevant articles and documents
Dendrimeric Sulfanyl Porphyrazines: Synthesis, Physico-Chemical Characterization, and Biological Activity for Potential Applications in Photodynamic Therapy
Mlynarczyk, Dariusz T.,Lijewski, Sebastian,Falkowski, Michal,Piskorz, Jaroslaw,Szczolko, Wojciech,Sobotta, Lukasz,Stolarska, Magdalena,Popenda, Lukasz,Jurga, Stefan,Konopka, Krystyna,Düzgüne?, Nejat,Mielcarek, Jadwiga,Goslinski, Tomasz
, p. 460 - 470 (2016)
Sulfanyl porphyrazines substituted at their periphery with different dendrimeric moieties up to their first generation were synthesized and characterized by photochemical and biological methods. The presence of a dendrimeric periphery enhanced the spectral properties of the porphyrazines studied. The singlet-oxygen-generation quantum yield of the obtained macrocycles ranged from 0.02 to 0.20 and was strongly dependent on the symmetry of the compounds and the terminal groups of the dendritic outer shell. The in vitro biological effects of three most promising tribenzoporphyrazines were examined; the results indicated their potential as photosensitizers for photodynamic therapy (PDT) against two oral squamous cell carcinoma cell lines derived from the tongue. The highest photocytotoxicity was found for sulfanyl tribenzoporphyrazine that possessed 4-[3,5-di(hydroxymethyl)phenoxy]butyl substituents with nanomolar IC50 values at 10 and 42 nm against CAL 27 and HSC-3 cell lines, respectively. Topic of cancer: Sulfanyl porphyrazines and tribenzoporphyrazines substituted at their periphery with different dendrimeric moieties up to their first generation were synthesized and characterized by photochemical and biological methods. The in vitro biological effects of three most promising tribenzoporphyrazines were examined and found to exhibit nanomolar IC50 values (see figure).
COMPOSITIONS AND METHODS RELATED TO MOLECULAR CONJUGATION
-
Page/Page column 72; 73, (2021/06/11)
The invention relates to activated Michael acceptor (AMA) compounds that can undergo conjugation with biomolecules containing Michael donor moieties, thereby providing plasma-stable antibody-drug conjugates (ADCs). Pharmaceutical compositions of the ADCs are disclosed as well. Also provided herein are a number of applications (e.g., therapeutic applications) in which the compositions are useful.
FUSED HETEROCYCLIC BENZODIAZEPINE DERIVATIVES AND USES THEREOF
-
Page/Page column 84, (2020/05/29)
The present disclosure provides compounds and compositions capable of extending lifespan, and methods of use thereof.